Juvenile rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 11, Issue 5, 1999, Pages 372-376

  Gallagher, Kerry T ^a   Bernstein, Bram ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ATHEROGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; OBESITY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLICATION; REVIEW; UVEITIS;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS;

EID: 0032755460     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199909000-00008     Document Type: Review

References (31)

1. Kiessling U, Doring E, Listing J, Meincke J, Schontube M, Strangfeld A, Zink A: Incidence and prevalence of juvenile chronic arthritis in East Berlin 1980-1988. J Rheumatol 1998, 25:1837-1843.
2. Arguedas O, Fasth A, Andersson-Gare B, Porras O: Juvenile chronic arthritis in urban San Jose, Costa Rica: a 2 year prospective study. J Rheumatol 1998, 25:1844-1850.
3. Dracou C, Constantinidou N, Constantopoulos A: Juvenile chronic arthritis profile in Greek children. Acta Paediatrica Japonica, 40:558-563.
4. Muller K, Herner EB, Stagg A, Bendtzen K, Woo P: Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 1998, 37:562-569. This study provides preliminary evidence for a role of reduced IL-10 production in the pathogenesis of systemic JRA.
5. Gattorno M, Picco P, Vignola S, Stalla F, Buoncompagni A, Pistoia V: Serum interleukin 12 concentration in juvenile chronic arthritis. Ann Rheum Dis 1998, 57:425-428.
6. Murray KJ, Grom AA, Thompson SD, Lieuwen D, Passo MH, Glass DN: Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthtitis and juvenile spondyloarthropathy: prominence of interleukin-4 in restricted disease. J Rheumatol 1998, 25:1388-1398. This paper describes different cytokine profiles in different JRA subtypes and suggests that IL-4 and IL-10 provide an anti-inflammatory effect in the synovial fluid in JRA.
7. Ozen S, Tucker LB, Miller LC: Identification of Th subsets in juvenile rheumatoid arthritis confirmed by intracellular cytokine staining. J Rheumatol 1998, 25:1651-1653.
8. DeBenedetti F, Pignatti P, Bernasconi S, Gerloni V, Matsushima K, Caporali R, Montecucco CM, Sozzani S, Fantini F, Martini A: Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis: relation to onset types, disease activity, and synovial fluid leukocytes. J Rheumatol 1999, 26:425-431.
9. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997, 6:315-325.
10. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P: A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998, 10:729-734. This paper provides some evidence for the importance of sIL-6r in addition to IL-6 in the pathogenesis of systemic JRA.
11. Schobitz B, Petershki G, Hemmann U, Heinrich PC, Holsboer F, Reul JM: FASEB J 1995, 9:659-664.
12. Fishman D, Faulds G, Jeffrey R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376. This paper provides evidence for a genotype associated with lower plasma IL-6 levels that may protect against the development of systemic JRA.
13. Mangge H, Schauenstein K: Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 1998, 10:471-480. A comprehensive review of the cytokine network in JRA by disease subtypes.
14. Tselepsis, AD, Elisaf M, Besis S, Karabina SAP, Chapman MJ, Siamopolou A: Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetythydrolase activity. Arthritis Rheum 1999, 42:373-383.
15. Khalkhali-Ellis Z, Moore TL, Hendrix MJC: Reduced levels of testosterone and dehydroepiandosterone sulphate in the serum and synovial fluid of juvenile rheumatoid arthritis patients correlates with disease severity. Clin Exp Rheumatol 1998, 753-756.
16. Verloes A, Curry C, Jamar M, Herens C, O'Lague P, Marks J, Sarda P, Blanchet P: Juvenile rheumatoid arthritis and del(22q11) syndrome: a non-random association. J Med Genet 1998, 35:943-947. This paper further expands understanding of the phenotypic expression of del(22q11).
17. Zulian F, Schumacher HR, Calore A, Goldsmith DP, Athreya BH: Juvenile arthritis in Turner's syndrome: a multicenter study. Clin Exp Rheumatol 1998, 16:489-494. This paper reports on the association with Turner's syndrome and polyarthritis.
18. Miller J: Specificity of daily fever spikes for systemic arthritis in children: a test of the ILAR/WHO criteria. J Rheumatol 1998, 25:1650-1651.
19. Bloom BJ, Tucker LB, Miller LC, Schaller JG: Fibrin d-dimer as a marker of disease activity in systemic onset juvenile rheumatoid arthritis. J Rheumatol 1998, 25:1620-1625. This paper provides data confirming the use of fibrin d-dimer as a marker of disease activity in systemic JRA.
20. Adebajo AO, Hall MA: The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998, 37:1240-1242.
21. Padeh S, Passwell JH: Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 1998, 41:1210-1214. This study provides evidence for the safety and efficacy of intraarticular steroid injections in the treatment of JRA.
22. Ravelli A, Vila S, Ramenghi B, Beluffi G, Zonta LA, Martini A: Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr 1998, 133:262-265.
23. Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH: The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999, 134:47-52. This study identifies factors associated with and without increased risk for methotrexate-related hepatotoxicity.
24. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR: Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951. This study identifies osteoclasts as the source of bone erosions.
25. Kotaniemi A, Savolainen A, Kroger H, Kautiainen H, Isomaki H: Development of bone mineral density at the lumbar spine and femoral neck in juvenile chronic arthritis: a prospective one year followup study. J Rheumatol 1998, 25:2450-2455.
26. Pereira RMR, Corrente JE, Chahade WH, Yoshinari NH: Evaluation by dual x-ray absorptiometry (DXA) of bone mineral density in children with juvenile chronic arthritis. Clin Exp Rheumatol 1998, 16:495-501.
27. Brik R, Keidar Z, Schapira D, Israel O: Bone mineral density and turnover in children with systemic juvenile chronic arthritis. J Rheumatol 1998, 25:990-992.
28. Kilmartin DJ, Forrester JV, Dick AD: Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Opthalmol 1998, 82:737-742. This paper documents the efficacy of cyclosporine in the treatment of refractory uveitis.
29. Kilmartin DJ, Forrester JV, Dick AD: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998, 352:35-36. This paper reports on the efficacy of mycophenolate mofetil in uveitis unresponsive to other forms of immunosuppression.
30. Weiss AH, Wallace CA, Sherry DD: Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998, 133:266-268.
31. Flato B, Aasland A, Vinje O, Forre O: Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998, 25:366-375. In addition to confirming improved outcomes in JRA, this paper provides additional data supporting early treatment with DMARDs.